Healyx Changes Lives by Treating Chronic Wounds

Lower-cost, more-effective treatments are the hallmark of many Fogarty Institute companies, and that is the principle Healyx is living up to with its device that provides gold standard care for a chronic problem at a significant cost reduction.

Non-healing wounds are a critical global issue, with over eight million Medicare patients afflicted at an annual cost of $31.7 billion in the U.S.

Q&A With Holly Rockweiler, CEO and Co-Founder of Madorra

A former Stanford Biodesign Fellow and Fogarty Institute entrepreneur, 32-year-old Holly Rockweiler has already had remarkable accomplishments early in her career, fluently moving her startup to the next level.

Most notably, Holly has parlayed Madorra’s impressive study results into securing funding, including winning several pitching competitions, despite the chronically challenging medtech fundraising environment.

New Fogarty Institute Company Lume Medical Developing a Large Bore Vascular Closure Device, a Key Benefit to Cardio Patients

When a cardiovascular intervention is called for, a less-invasive solution is always preferred – which is why percutaneous procedures, such as transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR) are on the rise.

But this trend hasn’t been without its drawbacks, as cardiologists and surgeons are now faced with the challenge of closing relatively large femoral access sites – ranging from three to eight millimeters in size – that are required to conduct these procedures.

A Better Kind of “Gut Check”

Often referred to as the “second brain,” the gut is garnering increased attention as mounting evidence shows the key role it plays far beyond digesting food in influencing our moods and general health. G-Tech Medical, a Fogarty Institute company, is playing a critical role in helping to better understand the complexities of our gut and its 500 million neurons.

START TYPING AND PRESS ENTER TO SEARCH